Abstract
Activating point mutations of the K-Ras oncogene are frequently found in a broad array of human malignancies, including hepatocellular carcinomas and lung adenocarcinomas. Even though these K-Ras mutations have been causally linked to the oncogenic process, different therapeutic approcahes to target Ras directly have failed in clinical trials. Therefore, in order to select better targets …